TRAVERE THERAPEUTICS INC. - COMMON STOCK

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

03 мар 2023 16:05:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

28 фев 2023 22:36:49 Источник Nasdaq GlobeNewswire

Travere Therapeutics Announces Proposed Public Offering of Common Stock

27 фев 2023 16:01:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

23 фев 2023 16:01:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

17 фев 2023 16:04:25 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results

16 фев 2023 16:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 фев 2023 17:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

08 фев 2023 16:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 янв 2023 19:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Provides Corporate Update and 2023 Outlook

09 янв 2023 07:00:01 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 янв 2023 16:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 дек 2022 17:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

16 ноя 2022 17:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease

15 ноя 2022 08:00:02 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

09 ноя 2022 16:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Third Quarter 2022 Financial Results

27 окт 2022 16:01:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022

26 окт 2022 16:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Report Third Quarter 2022 Financial Results

20 окт 2022 16:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy

13 окт 2022 16:05:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 окт 2022 17:00:00 Источник Nasdaq GlobeNewswire